Johnson & Johnson Submits Supplemental New Drug Application To FDA Seeking Approval Of SPRAVATO CIII Nasal Spray In Treatment-Resistant Depression
Portfolio Pulse from Benzinga Newsdesk
Johnson & Johnson has submitted a supplemental new drug application to the FDA for the approval of SPRAVATO CIII nasal spray, aimed at treating treatment-resistant depression.
July 22, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Johnson & Johnson has submitted a supplemental new drug application to the FDA for SPRAVATO CIII nasal spray, which is intended to treat treatment-resistant depression. This could potentially expand their product offerings and market reach in the pharmaceutical sector.
The submission of a supplemental new drug application to the FDA for SPRAVATO CIII nasal spray indicates a potential new product offering for Johnson & Johnson. If approved, this could lead to increased revenues and market share in the treatment-resistant depression segment, positively impacting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100